Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Grant E. Pickering
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 507
- Beta
- 1.22
- Country
- US
- Piotroski score
- 0 / 9 (Weak)
- Altman Z-score
- 11.41
Financials
Net Income
$-284.30MEBITDA
$-292.50MFree Cash Flow
$-532.46MEPS (diluted)
$-1.97Shares Outstanding (diluted)
144.49M+3835.7%Operating Expenses
$302.78MCash & Debt
$1.49BRevenue by Segment (annual)
$7.00BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-766.63M | $-5.63 |
| 2024 | $0.00 | $-463.93M | $-3.80 |
| 2023 | $0.00 | $-402.27M | $-4.14 |
| 2022 | $0.00 | $-223.49M | $-3.44 |
| 2021 | $0.00 | $-100.08M | $-1.93 |
| 2020 | $0.00 | $-89.22M | $-2.97 |
| 2019 | $0.00 | $-50.27M | $-14.10 |
| 2018 | $0.00 | $-29.48M | $-8.12 |
| 2017 | $0.00 | $-17.24M | $-4.84 |
Valuation
PCVXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
149+230.86%Social Signal Score
Mentions (25)
- Newsmarketbeat.com·12h ago·Neutral
Vaxcyte's VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial Vaxcyte NASDAQ: PCVX said its investigational 31-valent pneumococcal conjugate vaccine, VAX-31, met all pre-specified primary immunogenicity endpoints in the pivotal Phase III OPUS-1 trial in adults.
View source ↗ - News (RSS)investing·12h ago·Neutral
Why is Vaxcyte stock sliding in after-hours trading today?
View source ↗ - News (RSS)seekingalpha·13h ago·Neutral
Vaxcyte files separate $500M offerings for equity/pre-funded warrants and 2032 convertible notes
View source ↗ - News (Marketaux)seekingalpha.com·17h ago·Positive
Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate - Slideshow (NASDAQ:PCVX) 2026-10-05 Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate - Slideshow (NASDAQ:PCVX) 2026-10-05
View source ↗ - News (RSS)seekingalpha·17h ago·Neutral
Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate - Slideshow
View source ↗ - Newsglobenewswire.com·17h ago·Negative
…posed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes SAN CARLOS, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced underwritten public offerings of $500 million of its common stock and pre-funded warrants and $500 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in separate public offerings registered under the Securitie…
View source ↗ - Newsseekingalpha.com·20h ago·Positive
Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate Transcript Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate Transcript
View source ↗ - News (RSS)zerohedge·21h ago·Neutral
…+13%, BBD +12%) rallied as Flávio Bolsonaro surged to a surprise lead over Luiz Inácio Lula da Silva in the first round of the presidential election. Vaxcyte shares (PCVX) soar 56% after the pharmaceutical firm said that VAX-31, its experimental vaccine to prevent invasive pneumococcal disease (IPD) and pneumococcal pneumonia, met all primary endpoints in the OPUS-1 pivotal Phase 3 adult trial, compared to PCV20 and PCV21. Virtu Financial Inc. shares (VIRT) are up 3.3% after JPMorgan upgraded th…
View source ↗ - Newsproactiveinvestors.com·22h ago·Neutral
Vaxcyte shares surge on late-stage vaccine trial success Vaxcyte (NASDAQ:PCVX) shares surged 57% in morning trading on Monday after the biotechnology company said its experimental pneumococcal vaccine VAX-31 generated immune responses comparable to rival vaccines in a late-stage study. The results strengthened expectations that VAX-31 could compete with Pfizer's Prevnar 20 and Merck's Capvaxive in the adult pneumococcal vaccine market, which Jefferies estimates could reach $3 billion to $6 billi…
View source ↗ - Newsbarrons.com·23h ago·Neutral
Vaxcyte Stock Spikes 57% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, Jefferies says.
View source ↗ - Newsglobenewswire.com·1d ago·Negative
Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20® (PCV20) and/or Capvaxive® (PCV21)
View source ↗ - News (RSS)investing·1d ago·Neutral
Vaxcyte to present phase 3 trial data for vaccine candidate
View source ↗ - Newsglobenewswire.com·1d ago·Neutral
…hase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate SAN CARLOS, Calif., Oct. 04, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced it will host a webcast and conference call tomorrow, October 5, 2026 at 8:00 a.m. ET / 5:00 a.m. PT to present topline data from the OPUS-1 adult pivotal Phase 3 trial evaluating the safety, tolerability and immunogenicity of VAX-31, the Company's 31-valent pneumoco…
View source ↗ - News (RSS)yahoo·19d ago·Neutral
Vaxcyte (PCVX) Brings In Pharma Veterans As Its Big Test Nears
View source ↗ - News (Marketaux)finance.yahoo.com·28d ago·Positive
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know Vaxcyte is a clinical-stage bio[+310 characters]
View source ↗ - News (Marketaux)finance.yahoo.com·28d ago·Positive
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm Vaxcyte, Inc. is a cli[+207 characters]
View source ↗ - Newsfool.com·28d ago·Negative
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing Andrew Guggenhime surrendered 2,705 shares at $61.18 per share on August 31 and September 2, representing a transaction value of $165,492. The transaction size represents 2% of the total equity stake held before the filing.
View source ↗ - Newsfool.com·28d ago·Positive
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know The transactions represented a combined value of about $378,000 based on weighted average prices of $61.12 per share. Jim Wassil traded shares equal to 4% of the stake held before the filing.
View source ↗ - Newsfool.com·28d ago·Neutral
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm The disposition of 6,289 shares at $61.20 per share represented a transaction value of about $384,900. The transaction involved shares equal to 0.87% of the total equity stake held before the filing, resulting in a minor reduction of the overall position.
View source ↗ - News (RSS)yahoo·29d ago·Neutral
The Next Year Will Define Vaxcyte’s (PCVX) Vaccine Gamble
View source ↗ - News (RSS)investing·32d ago·Neutral
Vaxcyte appoints two executives, narrows trial timeline
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data Luis Jodar, Ph.D., Former Pfizer Chief Medical Officer for Vaccines and Infectious Diseases with Extensive Leadership Experience Across Clinical Development and Medical Affairs for Pneumococcal Conjugate Vaccines Prevnar 13 and Prevnar 20, Joins Vaxcyte as Chief Medical Officer
View source ↗ - Newsglobenewswire.com·39d ago·Neutral
Vaxcyte to Participate in Upcoming Investor Conferences SAN CARLOS, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in fireside chats and host one-on-one meetings at the following investor conferences:
View source ↗ - News (RSS)seekingalpha·48d ago·Neutral
Vaxcyte: Not Enough Safety Margin With Current Price
View source ↗ - News247wallst.com·50d ago·Neutral
If You Followed Seth Klarman Into Vaxcyte in May, He Was Already Long Gone Seth Klarman's Baupost Group eliminated its entire stake in Vaxcyte (NASDAQ:PCVX | PCVX Price Prediction) during the June quarter, according to the 13F filed August 13, 2026.
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $-2.12 per share
Typical surprise -8.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-1.97 vs $-2.06beat
- Wed, May 6$-2.30 vs $-1.78miss
- Tue, Feb 24$-1.80 vs $-1.53miss
- Tue, Nov 4$-1.56 vs $-1.27miss
- Wed, Aug 6$-1.22 vs $-1.12miss
- Wed, May 7$-1.04 vs $-1.02miss
Estimates and results for PCVX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PCVX officers and directors.
- Bought
- —
- Sold
- $7.3m
0 trades
41 trades
- Wassil Jimsold
- Wassil Jimsold
- Wassil Jimsold
- Wassil Jimsold
- Wassil Jimsold
- Wassil Jimsold
- Dhaliwal Harpreet S.sold
- Wassil Jimsold
59 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Ray Cisneroshouse · CA31 · disclosed Sep 7, 2026 (53d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jun 9, 2026 (27d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jun 9, 2026 (28d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed May 7, 2025 (22d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed May 7, 2025 (23d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed May 7, 2025 (9d later)Buy$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed Apr 14, 2025 (40d later)Sell$15,001 - $50,000
- Chris Jacobshouse · NY27 · disclosed Jan 20, 2023 (39d later)Sell$1,001 - $15,000
- Chris Jacobshouse · NY27 · disclosed Dec 12, 2022 (34d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.